4.4 Review

Emerging technologies and their impact on regulatory science

Journal

EXPERIMENTAL BIOLOGY AND MEDICINE
Volume 247, Issue 1, Pages 1-75

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/15353702211052280

Keywords

Emerging technologies; biomarkers; regulatory science; risk assessment; bioimaging; bioinformatics

Funding

  1. Danish Environmental Protection Agency [667-00208]
  2. Japan Agency for Medical Research and Development (AMED) [21be0304401j0005]
  3. US Environmental Protection Agency [RD84003201]
  4. National Center for Advancing Translational Sciences [U24 TR001950, U24 TR002633]
  5. National Institute of Environmental Health Sciences [P42 ES027704, P30 ES 029067]
  6. NIDA
  7. NIH [U24DK097193, R01CA163256]
  8. NIEHS [U2CES030857]
  9. NIH/NCATS [1UG3TR003264]
  10. NIH/NINDS/NCATS [UH3NS105703/UG3NS105703]
  11. EU's Horizon 2020 Research and Innovation program [766884]
  12. Netherlands Organ-on-Chip Initiative (NOCI) Gravitation grant of the Netherlands Organization for Scientific Research (NWO)
  13. Innovative Medicines Initiatives 2 Joint Undertaking [116106]
  14. EFPIA
  15. National Institutes of Health (NIH), National Institute of Environmental Health Sciences [U2CES030170]
  16. Cancer Research UK [CRUK C45982/A21808]
  17. China Scholarship Council (CSC) [201406010343]
  18. Georgia Cancer Coalition Distinguished Scholar Award

Ask authors/readers for more resources

There is a growing need for safety assessment of food, drugs, and personal care products, driven by the utilization of emerging cellular, molecular, and in silico technologies. The rapid advancement and convergence of these technologies may impact regulatory decisions and approvals, but the lack of thorough evaluation raises concerns about their readiness for regulatory application. Developing strategies to evaluate these new technologies and ensuring their appropriate and rapid incorporation into regulatory use is crucial for the regulatory science field to keep pace with advancements and prepare for emerging global challenges. Collaboration between the regulatory community and technology developers is essential to harness collective capabilities for evaluating new assessment tools effectively.
There is an evolution and increasing need for the utilization of emerging cellular, molecular and in silico technologies and novel approaches for safety assessment of food, drugs, and personal care products. Convergence of these emerging technologies is also enabling rapid advances and approaches that may impact regulatory decisions and approvals. Although the development of emerging technologies may allow rapid advances in regulatory decision making, there is concern that these new technologies have not been thoroughly evaluated to determine if they are ready for regulatory application, singularly or in combinations. The magnitude of these combined technical advances may outpace the ability to assess fit for purpose and to allow routine application of these new methods for regulatory purposes. There is a need to develop strategies to evaluate the new technologies to determine which ones are ready for regulatory use. The opportunity to apply these potentially faster, more accurate, and cost-effective approaches remains an important goal to facilitate their incorporation into regulatory use. However, without a clear strategy to evaluate emerging technologies rapidly and appropriately, the value of these efforts may go unrecognized or may take longer. It is important for the regulatory science field to keep up with the research in these technically advanced areas and to understand the science behind these new approaches. The regulatory field must understand the critical quality attributes of these novel approaches and learn from each other's experience so that workforces can be trained to prepare for emerging global regulatory challenges. Moreover, it is essential that the regulatory community must work with the technology developers to harness collective capabilities towards developing a strategy for evaluation of these new and novel assessment tools.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available